Mark Purcell
Stock Analyst
(n/a)
# 4,650
Out of 4,653 analysts
5
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $103.86 | +9.76% | 1 | Jan 23, 2024 | |
| SNY Sanofi | Initiates: Equal-Weight | $55 | $49.51 | +11.09% | 1 | Jan 23, 2024 | |
| GSK GSK | Initiates: Equal-Weight | $44 | $35.11 | +25.32% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $65.29 | +30.19% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $106.91 | +12.24% | 1 | Jan 23, 2024 |
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $103.86
Upside: +9.76%
Sanofi
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $49.51
Upside: +11.09%
GSK
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $35.11
Upside: +25.32%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $65.29
Upside: +30.19%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $106.91
Upside: +12.24%